share_log

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

Benzinga Real-time News ·  Jan 25, 2022 12:51

Here's a roundup of top developments in the biotech space over the last 24 hours.

Stocks In Focus

Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate

Pfizer, Inc.(NYSE:PFE) andBioNTech SE(NASDAQ:BNTX) announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an omicron-based vaccine candidate in healthy adults 18 through 55 years of age. The study will have three cohorts examining different regimens of the current Pfizer-BioNTech COVID-19 vaccine or an Omicron-based vaccine.

Opiant Announces Award of Incremental $2.2M BARDA Funding For Opioid Overdose Drug

Opiant Pharmaceuticals, Inc.(NASDAQ:OPNT...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
1
Comment Comment · Views 373

Recommended

Write a comment